Skip to main content

13-09-2021 | COVID-19 | News

News in brief

Better immune response with mRNA vs adenovirus-based COVID-19 vaccines in RMD patients

Claire Barnard

medwireNews: Preliminary results from a US study suggest that messenger (m)RNA vaccines against COVID-19 may elicit a stronger immune response than the adenovirus-based Johnson & Johnson (J&J) Janssen (JNJ-78436735) vaccine among people with rheumatic and musculoskeletal diseases (RMDs).

The researchers found that RMD patients who received an mRNA vaccine (n=994) were significantly more likely to produce antibodies against the receptor binding domain of the SARS-CoV-2 spike protein a median of 29 days after their second dose than those given the single-dose J&J vaccine (n=45), at rates of 92% versus 80%.

Median antibody titers were also significantly higher in the mRNA versus the J&J group (250.0 vs 9.7 units/mL), say Dorry Segev and colleagues from Johns Hopkins University in Baltimore, Maryland, USA.

The study was limited by small patient numbers and nonrandomized design, but these early results “suggest that patients with RMD who receive the J&J vaccine may have a more limited humoral response […] than recipients of the mRNA vaccine series,” write the study authors in a letter to the Annals of the Rheumatic Diseases.

They conclude: “Optimisation of J&J vaccine response in patients with RMD requires additional studies with larger sample size and evaluation of deeper immunophenotyping, including memory B cell and T cell responses.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

13 September 2021: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

Ann Rheum Dis 2021; doi:10.1136/annrheumdis-2021-221145

COVID-19 vaccination in patients with rheumatic diseases

Get answers to key questions with recommendations from professional organizations

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

JAK inhibitor safety

Data summary and expert discussion on the potential risks associated with JAK inhibitors.